This website uses cookies to enhance the user experience.
EP

Erlend Petter Skagseth1955

Shareholdings
1
7
Norway Business roles
18

Roles

Boards

NameRoleTotal operating incomeTotal equityShares
M
MITOSIS AS
Contact Person
-
5,454,063
100 %
directly
S
SARSIA IV AS
Chairman
-
13,773
15.77 %
indirectly
A
APIM THERAPEUTICS AS
Chairman
-
60,430,622
0.88 %
indirectly
P
PROPHYLIX PHARMA HOLDING AS
Board Member
-
19,595,007
0.62 %
indirectly
R
RECCURA THERAPEUTICS AS
Chairman
353,000
-940,572
-
S
SERCA PHARMACEUTICALS AS
Chairman
3,571,688
16,391,412
-
A
AVEXXIN ONCOLOGY AS
Chairman
-
-78,133
-
S
STIFTELSEN SINTEF
Alternate Member
364,551,000
3,024,072,000
-
S
SEAFARM SOLUTIONS AS
Board Member
152,750
1,347,958
-
C
CONNECT VEST
Board Member
5,257,202
1,938,608
-
Board Member
-
-
-
C
CAEDO ONCOLOGY AS
Chairman
-
14,416,685
-
P
PROPHYLIX AS
Board Member
-
-12,790,635
-
S
SINTEF AS
Alternate Member
2,610,115,000
779,044,000
-
S
SARSIA FOND III AS
Board Member
-
29,542,209
-
C
CALLUNA PHARMA POOLCO AS
Chairman
-
-
-
M
MED STORM INNOVATION AS
Board Member
4,094,446
1,590,884
-
Last update: Aug 23, 2024

Related industries5

  • Manufacturing
  • Professional, scientific and technical activities
  • Wholesale and retail trade; repair of motor vehicles and motorcycles
  • Activities of household as employers; undifferentiated goods- and services-producing activities of households for own account
  • Financial and insurance activities

Shares owned by Erlend Petter Skagseth

NameShare classTotal operating incomeTotal equityShare
M
MITOSIS AS
Ordinære aksjer
0
5,454,063
100 %
directly
S
SARSIA MANAGEMENT AS
24,562,324
8,572,152
15.77 %
indirectly
S
SARSIA IV AS
0
13,773
15.77 %
indirectly
S
SARSIA SEED AS
0
53,493,715
3.25 %
indirectly
A
AQUILOZ AS
0
-674,876
1.03 %
indirectly
A
APIM THERAPEUTICS AS
0
60,430,622
0.88 %
indirectly
S
SEA-HAWK NAVIGATION AS
3,977,545
233,702
0.68 %
indirectly
P
PROPHYLIX PHARMA HOLDING AS
0
19,595,007
0.62 %
indirectly

Limited to direct ownership positions of 0.5% or more.

Last update: May 24, 2024